GLP-1 Drugs Show Potential in Reducing Cancer Progression Risk
A new study led by Dr. Mark Orland from the Cleveland Clinic suggests that GLP-1 drugs, commonly used for diabetes and weight loss, may reduce the risk of cancer progression. The study analyzed over 10,000 patient records from the TriNetX Global Health Research Network, focusing on individuals with stage 1 to 3 cancers who began taking GLP-1 drugs post-diagnosis. The findings indicate that these drugs may lower the likelihood of tumors metastasizing, particularly in lung and breast cancers. The study, which will be presented at the American Society of Clinical Oncology’s annual meeting, highlights the potential anti-cancer effects of GLP-1 drugs. 
